Tag: macular edema and macular degeneration market demand

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Macular Edema and Macular Degeneration Industry Expected To Reach By 2029, Starting From 2025 Levels?

The market size for macular edema and macular degeneration has shown robust expansion in recent years. This market is projected to expand from $9.65 billion in 2024 to $10.33 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by factors such as an aging population, the prevalence of diabetes, increased awareness and early diagnosis, worldwide eye health initiatives, advancements in pharmaceuticals, and patient advocacy and support.

The macular edema and macular degeneration market is anticipated to experience robust expansion in the coming years. This market is projected to reach $13.44 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.8%. Key factors driving this growth during the forecast period include the adoption of personalized medicine strategies, increasing awareness in developing markets, an emphasis on combination treatments, the integration of teleophthalmology services, and the impact of global aging populations. Notable trends expected within this period involve innovations in sustained-release drug delivery, the incorporation of gene therapies, the emergence of new imaging technologies, customized treatment strategies guided by biomarkers, the use of teleophthalmology for distant monitoring, and progress in artificial intelligence applications for diagnostics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

What Are The Top Growth Drivers Impacting The Macular Edema and Macular Degeneration Market Outlook?

The expanding number of individuals with diabetes is anticipated to drive the advancement of the macular edema and macular degeneration market in the future. Diabetes is a chronic medical condition defined by elevated blood sugar (glucose) levels, which damages the blood vessels in the eye, potentially leading to conditions such as macular edema and macular degeneration. For example, in June 2024, data from The National Health Service (NHS England), a UK-based publicly funded healthcare system, showed that in 2023, the number of people identified by the NHS in England with pre-diabetes grew to 3,615,330, representing an 18% increase from 3,065,825 in 2022. Furthermore, among those under 40, cases surged nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising diabetes population is fueling the growth of the macular edema and macular degeneration market.

What Are The Major Segments Identified In The Macular Edema and Macular Degeneration Market?

The macular edema and macular degenerationmarket covered in this report is segmented –

1) By Treatment Type: Drug Therapy; Laser Treatment

2) By Application: Macular Edema; Diabetic Macular Edema (DME); Cystoid Macular Edema (CME); Macular Degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration

3) By End User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections; Steroid Injections; Oral Medications; Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation; Panretinal Photocoagulation (PRP); Subthreshold Laser Therapy; MicroPulse Laser Therapy

What Trends Are Redefining The Macular Edema and Macular Degeneration Market Dynamics?

Leading companies in the macular edema and macular degeneration market are concentrating on developing innovative products, such as Vabysmo (faricimab-svoa), to enhance their profitability. Vabysmo (faricimab-svoa) is a medication utilized for managing neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, in January 2022, Genentech Inc., a biotechnology corporation based in the US, received approval for Vabysmo (faricimab-svoa) from the Food and Drug Administration. This substance is a bispecific antibody designed to target vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), making it the first bispecific monoclonal antibody for both conditions. Faricimab holds the potential to become a highly successful medication for treating nAMD and DME, and its approval by the FDA and EU represents a significant accomplishment for Genentech and Roche.

Which Major Firms Are Strengthening Their Position In The Macular Edema and Macular Degeneration Industry?

Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

What Regional Growth Trends Are Shaping The Macular Edema and Macular Degeneration Market Outlook?

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Macular Edema and Macular Degeneration Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2025, By The Business Research Company

Age Related Macular Degeneration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/age-related-macular-degeneration-global-market-report

Macular Degeneration Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Alopecia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alopecia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Macular Edema and Macular Degeneration Market Size From 2025 to 2034?

The market size for macular edema and macular degeneration has seen significant expansion in the past few years. Its size is projected to rise from $9.65 billion in 2024 to $10.33 billion in 2025, averaging a compound annual growth rate (CAGR) of 7.0%. Factors driving growth in the historical period include an increase in the elderly population, high rates of diabetes, heightened awareness and early detection, global steps toward improved eye health, advances in pharmaceuticals, and reinforced patient advocacy and support.

The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to personalized medicine approaches, rising awareness in emerging markets, focus on combination therapies, integration with teleophthalmology services, global aging demographics. Major trends in the forecast period include advancements in sustained-release drug delivery, integration of gene therapies, development of novel imaging technologies, personalized treatment approaches based on biomarkers, teleophthalmology for remote monitoring, advancements in artificial intelligence for diagnostics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Which Factors and External Forces Are Driving Demand in the Macular Edema and Macular Degeneration Market?

The growth of the macular edema and macular degeneration market is anticipated to be fueled by an increasing diabetic population. Diabetes, a long-term medical condition, brings high blood sugar levels and can harm the eye’s blood vessels, potentially leading to macular edema and macular degeneration. For example, The National Health Service (NHS England), a public healthcare system in the UK, reported in June 2024 that the count of people identified with pre-diabetes rose to 3,615,330 in 2023, showing an 18% rise from 3,065,825 in 2022. Even more, there was nearly a 25% increase in cases among those under 40, increasing from 173,166 in 2022 to 216,440 in 2023. Thus, the proliferation of the diabetic population is acting as a catalyst for the growth of the macular edema and macular degeneration market.

Which Segments in the Macular Edema and Macular Degeneration Offer the Most Growth?

The macular edema and macular degenerationmarket covered in this report is segmented –

1) By Treatment Type: Drug Therapy; Laser Treatment

2) By Application: Macular Edema; Diabetic Macular Edema (DME); Cystoid Macular Edema (CME); Macular Degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration

3) By End User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections; Steroid Injections; Oral Medications; Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation; Panretinal Photocoagulation (PRP); Subthreshold Laser Therapy; MicroPulse Laser Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Macular Edema and Macular Degeneration Market?# Market?

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theMacular Edema and Macular Degeneration Market’s Growth?

Leading firms in the macular edema and macular degeneration market are striving to enhance their market profitability by creating innovative products such as Vabysmo (faricimab-svoa). This drug is utilized to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In January 2022, Genentech Inc., a biotech company based in the US, received FDA approval for Vabysmo (faricimab-svoa). It’s a bispecific antibody that functions by targeting the vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), marking it as the first dual-action monoclonal antibody for both conditions. Faricimab has the potential to be a game-changer in the treatment of nAMD and DME, and its approval by the FDA and EU signifies a significant achievement for both Genentech and Roche.

View the full report here:

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

What Are the Key Elements That Define the Macular Edema and Macular Degeneration Market?

Macular edema and macular degeneration are two different eye conditions that can affect vision. Macular edema is swelling in the part of the retina at the back of the eye, which can cause blurry vision. Macular degeneration is a condition that affects the macula, a part of the retina at the back of the eye that is responsible for central vision. They can be caused by many different conditions, including diabetic retinopathy, retinal vein occlusion, and inflammation, and include age, genetics, smoking, high blood pressure, and obesity.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Macular Edema and Macular Degeneration Market Grown from 2024 to 2025?

In recent times, the market size for macular edema and macular degeneration has experienced robust growth. Projected growth indicates an increase from $9.65 billion in 2024 to $10.43 billion in 2025, evidencing a compound annual growth rate (CAGR) of 8.1%. Various factors contributing to this growth during the historical period include an aging population, higher diabetes prevalence, more awareness and early diagnosis, worldwide initiatives toward eye health, innovative pharmaceutical developments, and increased patient advocacy and support.

What Growth Rate Is Anticipated for the Macular Edema and Macular Degeneration Market in the Coming Years?

In the coming years, robust growth is anticipated in the market size of macular edema and macular degeneration, with projections estimating it will expand to $13.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. Factors contributing to the growth in the predicted period include the application of personalized medicine, heightened awareness in developing markets, emphasis on combination therapies, collaboration with teleophthalmology services, and the impact of the worldwide aging population. Major trends for the forecasted timeframe include breakthroughs in sustained-release drug administration, the inclusion of gene therapies, the emergence of cutting-edge imaging technologies, customized treatment plans focusing on biomarkers, remote monitoring via teleophthalmology, and enhancements in diagnostic artificial intelligence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Who Are the Leading Companies in the Macular Edema and Macular Degeneration Market?

Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

What Are the Key Drivers of the Macular Edema and Macular Degeneration Market?

The growth of the macular edema and macular degeneration market is predicted to be fueled by the increasing diabetes population. Diabetes is a persistent health issue defined by elevated levels of glucose in the bloodstream. It impairs ocular blood vessels, leading to macular edema and macular degeneration. For example, The National Health Service (NHS England) reported in June 2024 that there was an 18% rise in identified pre-diabetic individuals in England, from 3,065,825 in 2022 to 3,615,330 in 2023. In addition, there was a nearly 25% rise in cases amongst those under 40, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the escalating diabetes prevalence is spurring the macular edema and macular degeneration market’s growth. Market Driver for Macular Edema and Macular Degeneration: Higher Occurrence of Eye Disorders Stimulates Market Growth

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

What Are the Key Market Segments in the Macular Edema and Macular Degeneration Industry?

The macular edema and macular degeneration market covered in this report is segmented –

1) By Treatment Type: Drug Therapy, Laser Treatment

2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

What Are the Latest Trends in the Macular Edema and Macular Degeneration Market?

To boost their profitability within the macular edema and macular degeneration market, key players are spearheading the development of innovative products such as Vabysmo (faricimab-svoa). This medication is primarily used to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In a significant instance, Genentech Inc., an American biotechnology firm, obtained FDA approval for Vabysmo (faricimab-svoa) in January 2022. It’s a bispecific antibody aiming at vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), marking its position as the first bispecific monoclonal antibody targeting both conditions. Faricimab carries the potential of becoming a best-selling drug for the treatment of nAMD and DME. Its approval from the FDA and EU is counted as a crucial achievement for both Genentech and Roche.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

What Are the Key Regional Markets in the Macular Edema and Macular Degeneration Industry?

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

This Report Delivers Insight On:

1. How big is the macular edema and macular degeneration market, and how is it changing globally?

2. Who are the major companies in the macular edema and macular degeneration market, and how are they performing?

3. What are the key opportunities and risks in the macular edema and macular degeneration market right now?

4. Which products or customer segments are growing the most in the macular edema and macular degeneration market?

5. What factors are helping or slowing down the growth of the macular edema and macular degeneration market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the macular edema and macular degeneration industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Macular Edema and Macular Degeneration Market, and What Factors Will Drive It?

The market for macular edema and macular degeneration has experienced healthy expansion recently. It is projected to increase in size from $9.65 billion in 2024 to $10.43 billion in 2025, representing a compound annual growth rate (CAGR) of 8.1%. Factors that have contributed to this growth historically include an older demographic, higher cases of diabetes, increased awareness and early detection, international efforts towards eye health, advances in pharmaceuticals, and the role of patient advocacy and support.

The market size for macular edema and macular degeneration is forecasted to experience significant growth in the upcoming years. By 2029, it’s projected to reach $13.71 billion, with a compound annual growth rate (CAGR) of 7.1%. This anticipated growth within the forecast period is due to various factors such as the implementation of personalized medicine strategies, increased awareness in developing markets, emphasis on combined therapies, and the incorporation of teleophthalmology services amidst a globally aging population. Future trends expected to shape the market during this period encompass advancements in prolonged-release drug distribution, the inclusion of gene therapies, the progression of innovative imaging techniques, individualized treatment methods utilizing biomarkers, the use of teleophthalmology for distance monitoring, and improvements in artificial intelligence for diagnostic purposes.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Which Factors and External Forces Are Driving Demand in the Macular Edema and Macular Degeneration Market?

The expansion of the macular edema and macular degeneration market is anticipated due to the escalating number of diabetes patients. High blood sugar levels characterize diabetes, a chronic health disorder which harms the eye’s blood vessels, leading to macular edema and macular degeneration. As stated by The National Health Service (NHS England), a UK-based state-funded healthcare system, in 2024, there was an 18% increase in pre-diabetes cases identified by NHS in England, rising from 3,065,825 in 2022 to 3,615,330 in 2023. Notably, in individuals younger than 40, there was almost a 25% rise in cases from 173,166 in 2022 to 216,440 in 2023. Thus, the growing diabetes population is fueling the progression of the macular edema and macular degeneration market.

Macular Edema and Macular Degeneration Market Driver: Rising Occurrences of Eye Conditions Boosts Macular Edema and Macular Degeneration Market

 

Which Segments in the Macular Edema and Macular Degeneration Offer the Most Growth?

The macular edema and macular degeneration market covered in this report is segmented –

1) By Treatment Type: Drug Therapy, Laser Treatment

2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

What Are the Fastest-Growing Geographies in the Macular Edema and Macular Degeneration Market?

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theMacular Edema and Macular Degeneration Market’s Growth?

Key businesses in the macular edema and macular degeneration market are channeling their efforts towards designing new products like Vabysmo (faricimab-svoa) to enhance their market profitability. Vabysmo is a medicinal product used in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). A notable example of this is Genentech Inc., a biotech company from the US, which received FDA approval for Vabysmo in January 2022. This medicine is the first of its kind bispecific monoclonal antibody, targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). With the potential to emerge as a popular solution for nAMD and DME, the approval of faricimab by the FDA and EU marks a significant milestone for Genentech and Roche.

View the full report here:

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

What Are the Key Elements That Define the Macular Edema and Macular Degeneration Market?

Macular edema and macular degeneration are two different eye conditions that can affect vision. Macular edema is swelling in the part of the retina at the back of the eye, which can cause blurry vision. Macular degeneration is a condition that affects the macula, a part of the retina at the back of the eye that is responsible for central vision. They can be caused by many different conditions, including diabetic retinopathy, retinal vein occlusion, and inflammation, and include age, genetics, smoking, high blood pressure, and obesity.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theMacular Edema and Macular Degeneration Market?

The upward trend in diabetes sufferers is anticipated to motivate a surge in the rise of the macular edema and macular degeneration market in the future. Diabetes, a chronic health issue defined by elevated blood glucose (sugar) levels, causes harm to the eye’s blood vessels, potentially causing macular edema and macular degeneration. For example, The National Health Service (NHS England), a publicly funded healthcare system based in the UK, stated in June 2024 that the number of people diagnosed with pre-diabetes by the NHS in England increased to 3,615,330 in 2023, up 18% from 3,065,825 in 2022. Moreover, pre-diabetic cases under the age of 40 soared almost 25%, growing from 173,166 in 2022 to 216,440 in 2023. Hence, the escalating diabetes population is fueling the expansion of the macular edema and macular degeneration market.

Macular Edema and Macular Degeneration Market Driver: Surge Of Eye Disorders Catalyses The Expansion of Macular Edema And Macular Degeneration Market

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

How Has the Macular Edema and Macular Degeneration Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The market size for macular edema and macular degeneration has experienced robust growth in the last few years. The market, which is projected at $9.65 billion in 2024, is poised to rise to $10.43 billion in 2025, marking a compound annual growth rate (CAGR) of 8.1%. The notable growth witnessed in the past can be ascribed to factors such as an aging population, an increase in diabetes cases, awareness and early detection, global strides in eye health, pharmaceutical breakthroughs, and sustained efforts towards patient advocacy and support.

The market for macular edema and macular degeneration is projected to experience robust growth in the coming years, reaching a valuation of $13.71 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 7.1%. This anticipated growth during the forecast period is linked to personalized medicine techniques, increasing awareness in burgeoning markets, emphasis on combined therapies, incorporation of teleophthalmology services, and a rise in global aging demographics. Key trends within this forecasted time include progress in sustained-release drug delivery, incorporation of gene therapies, the creation of new imaging technologies, personalized treatment models based on biomarkers, use of teleophthalmology for distant monitoring, and advancements in AI for diagnostics.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

Which Cutting-Edge Market Trends Are Expected to Drive theMacular Edema and Macular Degeneration Market’s Growth?

Key players in the machine learning operations sector are introducing innovative tools like GPT Monitoring for MLOps for real-time observation and cost control of GPT models, thereby enhancing the efficiency and performance of the engineering teams. The GPT Monitoring for MLOps technique leverages generative pre-trained transformers to augment the supervision and administration of machine learning operations, thus improving model performance tracking and informed decision-making. For example, New Relic, an American digital intelligence firm, rolled out New Relic Machine Learning Operations (MLOps) in March 2023 for real-time surveillance of applications developed using OpenAI’s GPT series APIs. This advanced feature enables the engineering teams to monitor performance and costs with a simple two-line code, thereby providing immediate observability and deep insights into GPT usage. It supports all current OpenAI GPT versions, giving companies the ability to optimize AI-centered applications and minimize operational costs.

What Are the Leading Market Players Impacting theMacular Edema and Macular Degeneration Market’s Growth Trend?

Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

How Are the Key Segments of the Macular Edema and Macular Degeneration Market Driving Opportunities and Innovations?

The macular edema and macular degeneration market covered in this report is segmented –

1) By Treatment Type: Drug Therapy, Laser Treatment

2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theMacular Edema and Macular Degeneration Market?# Market Expansion?

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2025, By The Business Research Company:

Hyperlipidemia Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Macular Degeneration Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Projected Compound Annual Growth Rate (CAGR) of the Macular Edema and Macular Degeneration Market from 2025 to 2034, and What Factors Influence It?

The market size for macular edema and macular degeneration has seen robust growth in the past few years. The market value is predicted to rise from $9.65 billion in 2024 to $10.43 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this historical growth include an aging population, the prevalence of diabetes, early detection and awareness, worldwide eye health initiatives, advancements in pharmaceuticals, and advocacy and support for patients.

The market for macular edema and macular degeneration is projected to experience robust expansion in the forthcoming years, escalating to $13.71 billion by 2029 with a CAGR of 7.1%. This growth during the forecast period is due to various factors such as the adoption of personalized medicine strategies, increased awareness in developing markets, emphasis on combination therapies, incorporation of teleophthalmology services, and worldwide aging demographics. Key trends expected during this projection period include the progression of sustained-release drug delivery systems, the incorporation of gene therapies, the creation of innovative imaging technologies, personalized treatment strategies based on biomarkers, the use of teleophthalmology for remote monitoring, and advancements in AI for diagnostic purposes.

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the macular edema and macular degeneration Market?

The growth of the macular edema and macular degeneration market is likely to be boosted by the expanding population of people with diabetes. Diabetes, a long-term medical condition characterized by elevated blood glucose (sugar) levels, can damage eye blood vessels leading to macular edema and macular degeneration. For example, The National Health Service (NHS England), a UK-based publicly funded healthcare system reported in June 2024 that there was an 18% rise in pre-diabetes cases to 3,615,330 in 2023, up from 3,065,825 in 2022. The rise of diabetes cases among those under 40 was particularly significant, up nearly 25% from 173,166 in 2022 to 216,440 in 2023. Therefore, this increasing rate of diabetes fuels the growth of the macular edema and macular degeneration market. The growth of the macular edema and macular degeneration market is also potentially influenced by an escalating prevalence of eye disorders. A wide spectrum of disorders can affect the visual system and potentially cause macular edema due to fluid leakage in the macula. The abnormal growth and leakage of blood vessels typical of wet AMD directly cause fluid accumulation in the macula. As an illustration, a report published by National Eye Health Week in September 2023 presented that the chief cause of blindness in the UK, late-stage age-related macular degeneration (AMD), is predicted to increase by 25% by 2032. The other eye disorders, early-stage AMD (drusen) will increase by 16%, cataracts by 25%, and glaucoma by 17% by 2032. Hence, the growing frequency of eye disorders propels the growth of the macular edema and macular degeneration market.

Request Your Free Macular Edema and Macular Degeneration Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Who Are the Leading Players Fueling Growth in the Macular Edema and Macular Degeneration Market?

Major companies operating in the macular edema and macular degeneration market report are:

• F. Hoffmann La Roche Ltd._x000D_

• AbbVie Inc._x000D_

• Bayer AG_x000D_

• Novartis AG_x000D_

• GlaxoSmithKline PLC_x000D_

What Are the Emerging Trends Shaping the Future of the Macular Edema and Macular Degeneration Market?

Primary entities functioning in the macular edema and macular degeneration market are centering their efforts on the development of outstanding products like Vabysmo (faricimab-svoa) to escalate their market gains. Vabysmo (faricimab-svoa) is a therapeutic drug implemented for the alleviation of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, Genentech Inc., a biotechnological company from the USA, received the approval for Vabysmo (faricimab-svoa) from the Food and Drug Administration earlier in January 2022. This medication is a bispecific antibody that aims at the vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), thus becoming the premier bispecific monoclonal antibody for both such illnesses. Faricimab holds great promise of transforming into a blockbuster treatment for nAMD and DME. The approval of it from FDA and EU marks a significant achievement for Genentech and Roche.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

What Are the Key Components of the Macular Edema and Macular Degeneration Market, and How Do Its Segments Perform?

The macular edema and macular degeneration market covered in this report is segmented –

1) By Treatment Type: Drug Therapy, Laser Treatment

2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)

2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

Which Regions Are Driving Growth in the Macular Edema and Macular Degeneration Market?

North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Defines the Scope of the Macular Edema and Macular Degeneration Market?

Macular edema and macular degeneration are two different eye conditions that can affect vision. Macular edema is swelling in the part of the retina at the back of the eye, which can cause blurry vision. Macular degeneration is a condition that affects the macula, a part of the retina at the back of the eye that is responsible for central vision. They can be caused by many different conditions, including diabetic retinopathy, retinal vein occlusion, and inflammation, and include age, genetics, smoking, high blood pressure, and obesity.

Browse Through More Similar Reports By The Business Research Company:

Hyperlipidemia Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Macular Degeneration Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: